(Reuters) – The U.S. Food and Drug Administration on Tuesday declined to approve MediWound Ltd’s topical treatment, NexoBrid, for burnt tissue, the company said.
The agency has identified issues related to the chemistry, manufacturing and controls section of the application and has requested additional information. (https://refini.tv/2T9LviX)
(Reporting by Trisha Roy in Bengaluru; Editing by Arun Koyyur)
